Jazz Pharma legal chief sells $289K in shares

Jazz Pharmaceuticals’ chief legal officer reported an automatic Rule 10b5-1 sale of 1,200 shares and continues to hold a sizable direct stake.

Rhea-AI Filing Summary

Jazz Pharmaceuticals plc (JAZZ) reported that Executive Vice President and Chief Legal Officer Neena M. Patil sold 1,200 ordinary shares on September 10, 2026 at an average price of $240.94 per share in an open-market or private transaction. The sale occurred automatically under a Rule 10b5-1 trading plan adopted on February 26, 2026 and is described as non-discretionary. Following this transaction, Patil directly holds 47,671 ordinary shares of Jazz Pharmaceuticals.

Insider Trade Summary 10b5-1

Net Seller: 1,200 shares

Net Sell 1 txn

Insider Patil Neena M

Role EVP & Chief Legal Officer

Sold 1,200 shs ($289K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares F1	1,200	$240.94	$289K

Holdings After Transaction: Ordinary Shares — 47,671 shares (Direct)

Footnotes (1)

1. F1. This transaction was made pursuant to a plan adopted by the reporting person on February 26, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

Key Figures

Shares sold: 1,200 shares Sale price per share: $240.94 per share Transaction value: $289,128 +2 more

5 metrics

Shares sold 1,200 shares Ordinary shares sold on September 10, 2026

Sale price per share $240.94 per share Average price for the September 10, 2026 sale

Transaction value $289,128 1,200 shares sold at $240.94 per share

Shares held after transaction 47,671 shares Direct holdings by Neena M. Patil following the sale

Rule 10b5-1 plan adoption date February 26, 2026 Date the trading plan governing this sale was adopted

Key Terms

Rule 10b5-1, automatic, discretionary transaction

3 terms

Rule 10b5-1 regulatory

"adopted by the reporting person on February 26, 2026 in accordance with Rule 10b5-1"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

automatic regulatory

"The transaction occurred automatically and does not represent a discretionary transaction"

discretionary transaction regulatory

"does not represent a discretionary transaction by the reporting person"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did JAZZ report for Neena M. Patil?

Neena M. Patil, Executive Vice President and Chief Legal Officer, reported a sale of 1,200 ordinary shares of Jazz Pharmaceuticals on September 10, 2026 in an open-market or private transaction.

At what price were the JAZZ shares sold in this Form 4 filing?

The 1,200 Jazz Pharmaceuticals ordinary shares were sold at an average price of $240.94 per share, resulting in a total reported transaction value of approximately $289,128.

How many JAZZ shares does Neena M. Patil hold after this sale?

After the reported sale, Neena M. Patil directly holds 47,671 ordinary shares of Jazz Pharmaceuticals, according to the Form 4 filing.

Was the JAZZ insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing states the sale was made under a Rule 10b5-1 trading plan adopted by Neena M. Patil on February 26, 2026, and that the transaction occurred automatically rather than as a discretionary trade.

What is the role of the insider involved in this JAZZ Form 4?

The reporting person, Neena M. Patil, serves as Executive Vice President & Chief Legal Officer of Jazz Pharmaceuticals, as disclosed in the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 06:38 PM Accepted by SEC EDGAR 09/14/2026 - 06:38 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patil Neena M

(Last) (First) (Middle)

5TH FL, WATERLOO EXCHANGE

WATERLOO RD

(Street)

DUBLIN 4

(City) (State) (Zip)

IRELAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	09/10/2026		S(1)		1,200	D	$240.94	47,671	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was made pursuant to a plan adopted by the reporting person on February 26, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

	By: /s/Paz Dizon, as attorney in fact For: Neena M Patil	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)